|
1
|
Friedrich P, Ortiz R, Strait K, Fuentes S,
Gamboa Y, Arambú I, Ah-Chu-Sanchez M, London W, Rodríguez-Galindo
C, Antillón-Klussmann F, et al: Central American Association of
Pediatric Hematologists Oncologists AHOPCA: Pediatric sarcoma in
Central America: Outcomes, challenges, and plans for improvement.
Cancer. 119:871–879. 2013. View Article : Google Scholar
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006. View Article : Google Scholar
|
|
4
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
|
|
5
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar
|
|
6
|
Zhang YE: Non-Smad signaling pathways of
the TGF-β family. Cold Spring Harb Perspect Biol. 9:92017.
View Article : Google Scholar
|
|
7
|
Batlle E and Massagué J: Transforming
growth factor-β signaling in immunity and cancer. Immunity.
50:924–940. 2019. View Article : Google Scholar
|
|
8
|
Walker RA and Dearing SJ: Transforming
growth factor beta 1 in ductal carcinoma in situ and invasive
carcinomas of the breast. Eur J Cancer. 28:641–644. 1992.
View Article : Google Scholar
|
|
9
|
Adekoya TO and Richardson RM: Cytokines
and chemokines as mediators of prostate cancer metastasis. Int J
Mol Sci. 21:212020. View Article : Google Scholar
|
|
10
|
Stolfi C, Troncone E, Marafini I and
Monteleone G: Role of TGF-beta and Smad7 in gut inflammation,
fibrosis and cancer. Biomolecules. 11:112020. View Article : Google Scholar
|
|
11
|
Xu S, Yang S, Sun G, Huang W and Zhang Y:
Transforming growth factor-beta polymorphisms and serum level in
the development of osteosarcoma. DNA Cell Biol. 33:802–806. 2014.
View Article : Google Scholar
|
|
12
|
Lamora A, Talbot J, Bougras G, Amiaud J,
Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann
MF, et al: Overexpression of smad7 blocks primary tumor growth and
lung metastasis development in osteosarcoma. Clin Cancer Res.
20:5097–5112. 2014. View Article : Google Scholar
|
|
13
|
Gellibert F, Woolven J, Fouchet MH,
Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S,
Wang R, et al: Identification of 1,5-naphthyridine derivatives as a
novel series of potent and selective TGF-beta type I receptor
inhibitors. J Med Chem. 47:4494–4506. 2004. View Article : Google Scholar
|
|
14
|
Ichida JK, Blanchard J, Lam K, Son EY,
Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, et
al: A small-molecule inhibitor of tgf-Beta signaling replaces sox2
in reprogramming by inducing nanog. Cell Stem Cell. 5:491–503.
2009. View Article : Google Scholar
|
|
15
|
Mei L, Sang W, Chen Z, Zheng L, Jin K, Lou
C, Huang W and He D: Small molecule inhibitor RepSox prevented
ovariectomy-induced osteoporosis by suppressing osteoclast
differentiation and bone resorption. J Cell Physiol. 233:9724–9738.
2018. View Article : Google Scholar
|
|
16
|
Fu Y, Huang C, Xu X, Gu H, Ye Y, Jiang C,
Qiu Z and Xie X: Direct reprogramming of mouse fibroblasts into
cardiomyocytes with chemical cocktails. Cell Res. 25:1013–1024.
2015. View Article : Google Scholar
|
|
17
|
Jajosky AN, Coad JE, Vos JA, Martin KH,
Senft JR, Wenger SL and Gibson LF: RepSox slows decay of CD34+
acute myeloid leukemia cells and decreases T cell immunoglobulin
mucin-3 expression. Stem Cells Transl Med. 3:836–848. 2014.
View Article : Google Scholar
|
|
18
|
Ide M, Jinnin M, Tomizawa Y, Wang Z,
Kajihara I, Fukushima S, Hashizume Y, Asano Y and Ihn H:
Transforming growth factor β-inhibitor Repsox downregulates
collagen expression of scleroderma dermal fibroblasts and prevents
bleomycin-induced mice skin fibrosis. Exp Dermatol. 26:1139–1143.
2017. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Jiang X, Shan J, Dai N, Zhong Z, Qing Y,
Yang Y, Zhang S, Li C, Sui J, Ren T, et al: Apurinic/apyrimidinic
endonuclease 1 regulates angiogenesis in a transforming growth
factor β-dependent manner in human osteosarcoma. Cancer Sci.
106:1394–1401. 2015. View Article : Google Scholar
|
|
21
|
Lu KH, Su SC, Lin CW, Hsieh YH, Lin YC,
Chien MH, Reiter RJ and Yang SF: Melatonin attenuates osteosarcoma
cell invasion by suppression of C-C motif chemokine ligand 24
through inhibition of the c-Jun N-terminal kinase pathway. J Pineal
Res. 65:e125072018. View Article : Google Scholar
|
|
22
|
Sun Y, Xia P, Zhang H, Liu B and Shi Y:
P53 is required for Doxorubicin-induced apoptosis via the TGF-beta
signaling pathway in osteosarcoma-derived cells. Am J Cancer Res.
6:114–125. 2015.
|
|
23
|
Wang H, Zhang T, Sun W, Wang Z, Zuo D,
Zhou Z, Li S, Xu J, Yin F, Hua Y, et al: Erianin induces G2/M-phase
arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway
in human osteosarcoma cells in vitro and in vivo. Cell Death Dis.
7:e22472016. View Article : Google Scholar
|
|
24
|
Wang S, Li H, Chen S, Wang Z, Yao Y, Chen
T, Ye Z and Lin P: Andrographolide induces apoptosis in human
osteosarcoma cells via the ROS/JNK pathway. Int J Oncol.
56:1417–1428. 2020.
|
|
25
|
Wang Y, Deng X, Yu C, Zhao G, Zhou J,
Zhang G, Li M, Jiang D, Quan Z and Zhang Y: Synergistic inhibitory
effects of capsaicin combined with cisplatin on human osteosarcoma
in culture and in xenografts. J Exp Clin Cancer Res. 37:2512018.
View Article : Google Scholar
|
|
26
|
Jie Z, Xie Z, Zhao X, Sun X, Yu H, Pan X,
Shen S, Qin A, Fang X and Fan S: Glabridin inhibits osteosarcoma
migration and invasion via blocking the p38- and JNK-mediated
CREB-AP1 complexes formation. J Cell Physiol. 234:4167–4178. 2019.
View Article : Google Scholar
|
|
27
|
Lin RC, Yang SF, Chiou HL, Hsieh SC, Wen
SH, Lu KH and Hsieh YH: Licochalcone A-induced apoptosis through
the activation of p38MAPK pathway mediated mitochondrial pathways
of apoptosis in human osteosarcoma cells in vitro and in vivo.
Cells. 8:82019. View Article : Google Scholar
|
|
28
|
Lu KH, Chen PN, Hsieh YH, Lin CY, Cheng
FY, Chiu PC, Chu SC and Hsieh YS: 3-Hydroxyflavone inhibits human
osteosarcoma U2OS and 143B cells metastasis by affecting EMT and
repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways
and reduces 143B tumor growth in vivo. Food Chem Toxicol.
97:177–186. 2016. View Article : Google Scholar
|
|
29
|
Goorin AM, Harris MB, Bernstein M,
Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M
and Grier HE: Phase II/III trial of etoposide and high-dose
ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric
oncology group trial. J Clin Oncol. 20:426–433. 2002. View Article : Google Scholar
|
|
30
|
Kempf-Bielack B, Bielack SS, Jürgens H,
Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G,
Kabisch H, et al: Osteosarcoma relapse after combined modality
therapy: An analysis of unselected patients in the Cooperative
Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
View Article : Google Scholar
|
|
31
|
Bierie B and Moses HL: Tumour
microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar
|
|
32
|
Friedman E, Gold LI, Klimstra D, Zeng ZS,
Winawer S and Cohen A: High levels of transforming growth factor
beta 1 correlate with disease progression in human colon cancer.
Cancer Epidemiol Biomarkers Prev. 4:549–554. 1995.
|
|
33
|
Wikström P, Stattin P, Franck-Lissbrant I,
Damber JE and Bergh A: Transforming growth factor beta1 is
associated with angiogenesis, metastasis, and poor clinical outcome
in prostate cancer. Prostate. 37:19–29. 1998. View Article : Google Scholar
|
|
34
|
Roberts AB and Wakefield LM: The two faces
of transforming growth factor beta in carcinogenesis. Proc Natl
Acad Sci USA. 100:8621–8623. 2003. View Article : Google Scholar
|
|
35
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar
|
|
36
|
Costanza B, Umelo IA, Bellier J,
Castronovo V and Turtoi A: Stromal modulators of TGF-β in cancer. J
Clin Med. 6:62017. View Article : Google Scholar
|
|
37
|
Matsuyama S, Iwadate M, Kondo M, Saitoh M,
Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K,
et al: SB-431542 and Gleevec inhibit transforming growth
factor-beta-induced proliferation of human osteosarcoma cells.
Cancer Res. 63:7791–7798. 2003.
|
|
38
|
Franchi A, Arganini L, Baroni G, Calzolari
A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML and Zampi
G: Expression of transforming growth factor beta isoforms in
osteosarcoma variants: Association of TGF beta 1 with high-grade
osteosarcomas. J Pathol. 185:284–289. 1998. View Article : Google Scholar
|
|
39
|
Mohseny AB, Cai Y, Kuijjer M, Xiao W, van
den Akker B, de Andrea CE, Jacobs R, ten Dijke P, Hogendoorn PC and
Cleton-Jansen AM: The activities of Smad and Gli mediated
signalling pathways in high-grade conventional osteosarcoma. Eur J
Cancer. 48:3429–3438. 2012. View Article : Google Scholar
|
|
40
|
Jang CW, Chen CH, Chen CC, Chen JY, Su YH
and Chen RH: TGF-beta induces apoptosis through Smad-mediated
expression of DAP-kinase. Nat Cell Biol. 4:51–58. 2002. View Article : Google Scholar
|
|
41
|
Hannon GJ and Beach D: p15INK4B is a
potential effector of TGF-beta-induced cell cycle arrest. Nature.
371:257–261. 1994. View Article : Google Scholar
|
|
42
|
Reynisdóttir I, Polyak K, Iavarone A and
Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce
cell cycle arrest in response to TGF-beta. Genes Dev. 9:1831–1845.
1995. View Article : Google Scholar
|
|
43
|
Ghelli Luserna di Rora'AIacobucci I and
Martinelli G: The cell cycle checkpoint inhibitors in the treatment
of leukemias. J Hematol Oncol. 10:772017. View Article : Google Scholar
|
|
44
|
Wang JL, Quan Q, Ji R, Guo XY, Zhang JM,
Li X and Liu YG: Isorhamnetin suppresses PANC-1 pancreatic cancer
cell proliferation through S phase arrest. Biomed Pharmacother.
108:925–933. 2018. View Article : Google Scholar
|
|
45
|
Szmyd R, Niska-Blakie J, Diril MK, Renck
Nunes P, Tzelepis K, Lacroix A, van Hul N, Deng LW, Matos J,
Dreesen O, et al: Premature activation of Cdk1 leads to mitotic
events in S phase and embryonic lethality. Oncogene. 38:998–1018.
2019. View Article : Google Scholar
|
|
46
|
Koff A, Giordano A, Desai D, Yamashita K,
Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts
JM: Formation and activation of a cyclin E-cdk2 complex during the
G1 phase of the human cell cycle. Science. 257:1689–1694. 1992.
View Article : Google Scholar
|
|
47
|
Girard F, Strausfeld U, Fernandez A and
Lamb NJ: Cyclin A is required for the onset of DNA replication in
mammalian fibroblasts. Cell. 67:1169–1179. 1991. View Article : Google Scholar
|
|
48
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View Article : Google Scholar
|
|
49
|
Yeh HW, Lee SS, Chang CY, Lang YD and Jou
YS: A new switch for TGFβ in cancer. Cancer Res. 79:3797–3805.
2019. View Article : Google Scholar
|
|
50
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar
|
|
51
|
Morrison CD, Parvani JG and Schiemann WP:
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer
Lett. 341:30–40. 2013. View Article : Google Scholar
|
|
52
|
Yu X, Yustein JT and Xu J: Research models
and mesenchymal/epithelial plasticity of osteosarcoma. Cell Biosci.
11:942021. View Article : Google Scholar
|
|
53
|
Yang G, Yuan J and Li K: EMT transcription
factors: Implication in osteosarcoma. Med Oncol. 30:6972013.
View Article : Google Scholar
|
|
54
|
Sharili AS, Allen S, Smith K, Hargreaves
J, Price J and McGonnell I: Expression of Snail2 in long bone
osteosarcomas correlates with tumour malignancy. Tumour Biol.
32:515–526. 2011. View Article : Google Scholar
|
|
55
|
Wensman H, Göransson H, Leuchowius KJ,
Strömberg S, Pontén F, Isaksson A, Rutteman GR, Heldin NE, Pejler G
and Hellmén E: Extensive expression of craniofacial related
homeobox genes in canine mammary sarcomas. Breast Cancer Res Treat.
118:333–343. 2009. View Article : Google Scholar
|
|
56
|
Wu J, Liao Q, He H, Zhong D and Yin K:
TWIST interacts with β-catenin signaling on osteosarcoma cell
survival against cisplatin. Mol Carcinog. 53:440–446. 2014.
View Article : Google Scholar
|
|
57
|
Chen J, Song Y, Yang J, Gong L, Zhao P,
Zhang Y and Su H: The up-regulation of cysteine-rich protein 61
induced by transforming growth factor beta enhances osteosarcoma
cell migration. Mol Cell Biochem. 384:269–277. 2013. View Article : Google Scholar
|
|
58
|
Huang Y, Yang Y, Gao R, Yang X, Yan X,
Wang C, Jiang S and Yu L: RLIM interacts with Smurf2 and promotes
TGF-β induced U2OS cell migration. Biochem Biophys Res Commun.
414:181–185. 2011. View Article : Google Scholar
|
|
59
|
Kunita A, Kashima TG, Ohazama A,
Grigoriadis AE and Fukayama M: Podoplanin is regulated by AP-1 and
promotes platelet aggregation and cell migration in osteosarcoma.
Am J Pathol. 179:1041–1049. 2011. View Article : Google Scholar
|
|
60
|
Sung JY, Park SY, Kim JH, Kang HG, Yoon
JH, Na YS, Kim YN and Park BK: Interferon consensus
sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal
transition (EMT)-like phenomena, cell-motility, and invasion via
TGF-β signaling in U2OS cells. Cell Death Dis. 5:e12242014.
View Article : Google Scholar
|
|
61
|
Borok Z: Role for alpha3 integrin in EMT
and pulmonary fibrosis. J Clin Invest. 119:7–10. 2009.
|
|
62
|
Javelaud D and Mauviel A: Crosstalk
mechanisms between the mitogen-activated protein kinase pathways
and Smad signaling downstream of TGF-beta: Implications for
carcinogenesis. Oncogene. 24:5742–5750. 2005. View Article : Google Scholar
|
|
63
|
Chueh FS, Chen YY, Huang AC, Ho HC, Liao
CL, Yang JS, Kuo CL and Chung JG: Bufalin-inhibited migration and
invasion in human osteosarcoma U-2 OS cells is carried out by
suppression of the matrix metalloproteinase-2, ERK, and JNK
signaling pathways. Environ Toxicol. 29:21–29. 2014. View Article : Google Scholar
|
|
64
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008.
View Article : Google Scholar
|
|
65
|
Jung O and Lee SY: Synergistic anticancer
effects of timosaponin AIII and ginsenosides in MG63 human
osteosarcoma cells. J Ginseng Res. 43:488–495. 2019. View Article : Google Scholar
|
|
66
|
Liao CL, Lai KC, Huang AC, Yang JS, Lin
JJ, Wu SH, Gibson Wood W, Lin JG and Chung JG: Gallic acid inhibits
migration and invasion in human osteosarcoma U-2 OS cells through
suppressing the matrix metalloproteinase-2/-9, protein kinase B
(PKB) and PKC signaling pathways. Food Chem Toxicol. 50:1734–1740.
2012. View Article : Google Scholar
|
|
67
|
Lamora A, Mullard M, Amiaud J, Brion R,
Heymann D, Redini F and Verrecchia F: Anticancer activity of
halofuginone in a preclinical model of osteosarcoma: Inhibition of
tumor growth and lung metastases. Oncotarget. 6:14413–14427. 2015.
View Article : Google Scholar
|
|
68
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar
|
|
69
|
Nishihira J, Ishibashi T, Fukushima T, Sun
B, Sato Y and Todo S: Macrophage migration inhibitory factor (MIF):
Its potential role in tumor growth and tumor-associated
angiogenesis. Ann NY Acad Sci. 995:171–182. 2003. View Article : Google Scholar
|
|
70
|
Ogawa H, Nishihira J, Sato Y, Kondo M,
Takahashi N, Oshima T and Todo S: An antibody for macrophage
migration inhibitory factor suppresses tumour growth and inhibits
tumour-associated angiogenesis. Cytokine. 12:309–314. 2000.
View Article : Google Scholar
|
|
71
|
Yaddanapudi K, Putty K, Rendon BE, Lamont
GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW and Mitchell RA:
Control of tumor-associated macrophage alternative activation by
macrophage migration inhibitory factor. J Immunol. 190:2984–2993.
2013. View Article : Google Scholar
|
|
72
|
Li Y, Li X, Lu Y, Chaurasiya B, Mi G, Shi
D, Chen D, Webster TJ, Tu J and Shen Y: Co-delivery of Poria cocos
extract and doxorubicin as an 'all-in-one' nanocarrier to combat
breast cancer multidrug resistance during chemotherapy.
Nanomedicine. 23:1020952020. View Article : Google Scholar
|
|
73
|
Xu J, Wang H, Hu Y, Zhang YS, Wen L, Yin
F, Wang Z, Zhang Y, Li S, Miao Y, et al: Inhibition of CaMKIIα
activity enhances antitumor effect of fullerene C60 nanocrystals by
suppression of autophagic degradation. Adv Sci (Weinh).
6:18012332019. View Article : Google Scholar
|
|
74
|
Zhang Y, Wang F, Li M, Yu Z, Qi R, Ding J,
Zhang Z and Chen X: Self-stabilized hyaluronate nanogel for
intracellular codelivery of doxorubicin and cisplatin to
osteosarcoma. Adv Sci (Weinh). 5:17008212018. View Article : Google Scholar
|
|
75
|
Li D, Xu W, Li P, Ding J, Cheng Z, Chen L,
Yan L and Chen X: Self-targeted polysaccharide prodrug suppresses
orthotopic hepatoma. Mol Pharm. 13:4231–4235. 2016. View Article : Google Scholar
|
|
76
|
Wang J, Li Z, Wang Z, Yu Y, Li D, Li B and
Ding J: Nanomaterials for combinational radio-immuno oncotherapy.
Adv Funct Mater. 30:19106762020. View Article : Google Scholar
|
|
77
|
Zhao D, Zhu T, Li J, Cui L, Zhang Z,
Zhuang X and Ding J: Poly(lactic-co-glycolic acid)-based composite
bone-substitute materials. Bioact Mater. 6:346–360. 2020.
View Article : Google Scholar
|
